Pharmacokinetics of colistin in an adolescent boy with extensive burn injury

Journal of Burn Care and Research

Volumn 32, Issue 1, 2011, Pages

  Healy, Daniel P ^a   Sombun, Amy D ^a   Gardner, Jason C ^a   Good, Kathy ^a   Durkee, Paula J ^a   Toner, Lucy ^a   Rieman, Mary T ^a   Neely, Alice N ^a,b   Kagan, Richard J ^a,b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; COLISTIN; FLUCONAZOLE; IMIPENEM;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADOLESCENT; ARTICLE; BODY SURFACE; BURN; CASE REPORT; DRUG ELIMINATION; DRUG HALF LIFE; HEMODIALYSIS; HUMAN; MALE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; SALVAGE THERAPY; SEPTIC SHOCK; SKIN NECROSIS; WOUND INFECTION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ACUTE KIDNEY INJURY; ADOLESCENT; ANTI-BACTERIAL AGENTS; BURNS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FATAL OUTCOME; HUMANS; MALE; SHOCK, SEPTIC;

EID: 79151471886     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0b013e318203352a     Document Type: Article

References (22)

1. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
3. Goverman J, Weber JM, Keaney TJ, Sheridan RL. Intravenous colistin for the treatment of multi-drug resistant, gramnegative infection in the pediatric burn population. J Burn Care Res 2007;28:421-6.
4. Trottier V, Segura PG, Namias N, King D, Pizano LR, Schulman CI. Outcomes of Acinetobacter baumannii infection in crucially ill burned patients. J Burn Care Res 2007;28: 248-54. (Pubitemid 46411561)
5. Albrecht MA, Griffith ME, Murray CK, et al. Impact of Acinetobacter infection on the mortality of burn patients. J Am Coll Surg 2006;203:546-50.
6. Neely AN, Gardner J, Durkee P, et al. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J Burn Care Res 2009;30:19-29.
7. Maragakis LL, Perl TM. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis 2008;46:1254-63.
8. Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med 2008;358:1271-81.
9. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 1999;44:319-27.
10. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40:S99-104.
11. Bergman SJ, Speil C, Short M, Koirala J. Pharmacokinetic and pharmacodynamic aspects of antibiotic use in high-risk populations. Infect Dis Clin North Am 2007;21:821-46.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
13. Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45: 781-5.
14. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010;54:1117-24.
15. Markou N, Markantonis SL, Dimitrakis E, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gramnegative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51.
16. Li J, Rayner CR, Nation RL, et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 2005;49:4814-5.
17. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
18. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-Systems Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;49:325-7.
19. Colistimethate for Injection, USP [package insert]. Minneapolis, MN: Paddock Laboratories, Inc; 2005.
20. Li J, Rayner CR, Nation RL, et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946-50.
21. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004; 53:837-40.
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 20th informational supplement. CLSI M100-S20. 2010. Wayne, PA: Clinical and Laboratory Standards Institute.